Xenon Pharmaceuticals Inc.
XENE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.27 | -0.52 | -1.16 | -0.15 |
| FCF Yield | -6.04% | -4.90% | -4.24% | -5.25% |
| EV / EBITDA | -12.38 | -13.98 | -18.32 | -15.31 |
| Quality | ||||
| ROIC | -35.93% | -22.76% | -17.64% | -14.15% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.77 | 0.80 | 0.79 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -33.56% | 2,641,680.63% |
| Free Cash Flow Growth | -22.21% | -48.97% | -41.61% | -40.96% |
| Safety | ||||
| Net Debt / EBITDA | 0.57 | 0.65 | 0.37 | 2.14 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -722.87 | -18.73 | 38.15 | 54.74 |